ReciBioPharm - An optimized Plasmid DNA platform to accelerate the path to clinic and commercialization

External Webinar | Webinar

Overview

  • Assessing key parameters of the upstream process to achieve high titer while maintaining desired integrity.
  • Customizing the downstream process to address the different needs from supercoil plasmid and linear isoform.
  • A platform approach with integrated processes and analytical toolboxes to accelerate plasmid development to manufacturing.
This content is provided by Recipharm AB, and any views and opinions expressed do not necessarily reflect those of Biopharma-Reporter.com

Speakers

Jing Zhu
Jing Zhu
Vice President, Nucleic Acid & Viral Vector Technology
AAV Process Development

View webinar

Thank you, you can now watch the webinar.

Latest Related Resources

Supporting first lyophilised mRNA vaccine to trial

Supporting first lyophilised mRNA vaccine to trial

Content provided by Recipharm AB

Case Study

When Arcturus presented its mRNA vaccine candidate to Recipharm, it was at the stage of a frozen product, a ready-to-administer sterile injectable for Phase I & II clinical trials.

Supplier Info Centre

Recipharm-AB.png

For more product information visit Recipharm AB.